Adagio Medical proposes 1-for-10 to 1-for-500 reverse split
The proposal comes as Nasdaq bid-price and equity deficiencies remain unresolved, with a delisting notice expected after December 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Adagio Medical Holdings, Inc. (ADGM) asks stockholders to approve alternate charter amendments authorizing a reverse split of one-for-10 to one-for-500, with the Board choosing the ratio and whether and when to proceed. The Board could implement only one split or none; if it does not act within 12 months after the October 23, 2026 meeting, further stockholder approval would be required. If implemented, the split would leave 210,000,000 authorized common shares, increasing shares available for future issuance.
As of October 13, 2026, Adagio had not regained Nasdaq’s $1.00 minimum bid-price or $2,500,000 stockholders’ equity requirements; it submitted an equity-compliance plan on September 28. If Nasdaq accepts the plan, it may grant up to 180 calendar days. Adagio expects Nasdaq to provide a delisting notice after December 9, 2026, and says it intends to appeal a delisting determination. The split is intended to address the bid-price requirement, but Adagio gives no assurance it will restore compliance.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Nasdaq bid-price and equity requirements remained unmet; delisting notice expected after December 9, 2026.
- Moderate point. Forward-looking: it has not happened yet and may not happen.A proposed split would leave 210,000,000 authorized common shares and increase future issuance capacity.
Key Figures
Key Terms
Minimum Bid Price Requirement regulatory
Stockholders’ Equity Requirement regulatory
broker non-votes regulatory
cash in lieu of fractional shares financial
Compensation Summary
- Approve alternate amendments authorizing, but not requiring, a Board-selected 1-for-10 to 1-for-500 reverse split.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When could an ADGM reverse stock split take effect?
How would ADGM calculate cash for fractional shares after a reverse split?
AI-generated analysis. How Rhea-AI works. Not financial advice.
TABLE OF CONTENTS
☐ | Preliminary Proxy Statement |
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☒ | Definitive Proxy Statement |
☐ | Definitive Additional Materials |
☐ | Soliciting Material under §240.14a-12 |
Adagio Medical Holdings, Inc. |
(Name of Registrant as Specified in Its Charter) |
(Name of Person(s) Filing Proxy Statement if other than the Registrant) |
☒ | No fee required |
☐ | Fee paid previously with preliminary materials |
☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
TABLE OF CONTENTS

1. | To approve a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect, at the option of the Company’s Board of Directors, a reverse stock split of our common stock at a ratio in the range of 1-for-10 to 1-for-500, inclusive, with such ratio to be determined by the Company’s Board of Directors in its sole discretion. We refer to this proposal as the “Reverse Stock Split Proposal” or “Proposal No. 1”. |
2. | To conduct any other business properly brought before the meeting. |
By Order of the Board of Directors. | |||
/s/ Deborah Kaster | |||
Deborah Kaster Chief Financial Officer and Chief Business Officer Laguna Hills, CA October 13, 2026 | |||
You are cordially invited to attend the virtual Special Meeting. You will not be able to attend the Special Meeting in person. Whether or not you expect to attend the meeting, please complete, date, sign and return the enclosed proxy, or vote over the telephone or the internet as instructed in these materials, as promptly as possible in order to ensure your representation at the meeting. A return envelope (which is postage prepaid if mailed in the United States) has been provided for your convenience. Even if you have voted by proxy, you may still vote online if you attend the virtual Special Meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder. | ||
TABLE OF CONTENTS
Page | |||
PROXY STATEMENT | 1 | ||
PROPOSAL NO. 1 – APPROVAL OF A SERIES OF ALTERNATE AMENDMENTS TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF OUR COMMON STOCK | 6 | ||
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT | 15 | ||
OTHER INFORMATION FOR STOCKHOLDERS | 17 | ||
APPENDIX A – CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION | A-1 | ||
TABLE OF CONTENTS
TABLE OF CONTENTS
• | Proposal No. 1 – To approve a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect, at the option of the Board, a reverse stock split of our common stock at a ratio in the range of 1-for-10 to 1-for-500, inclusive (the “Reverse Stock Split”), with such ratio to be determined by the Board in its sole discretion. |
TABLE OF CONTENTS
By Internet | By Telephone | By Mail | During the Meeting | ||||||
You may vote your shares from any location in the world at www.proxyvote.com (you will need the control number printed on your proxy card) | You may vote your shares by calling 1-800-690-6903 and following the instructions on your proxy card. | If you received a proxy card by mail, you may vote by completing, dating and signing the proxy card and promptly mailing it in the postage-paid envelope provided. | To vote at the meeting, visit www.virtualshareholdermeeting.com/ADGM2026SM (you will need the control number printed on your proxy registration confirmation email) | ||||||
TABLE OF CONTENTS
• | You may submit another properly completed proxy card with a later date. |
• | You may grant a subsequent proxy by telephone or through the internet. |
• | You may send a timely written notice that you are revoking your proxy to Adagio’s Corporate Secretary at 26051 Merit Circle, Suite 102, Laguna Hills, CA, 92653. Such notice will be considered timely if it is received at the indicated address by the close of business on the business day one week preceding the date of the Special Meeting. |
• | You may attend the Special Meeting and vote online. Simply attending the Special Meeting will not, by itself, revoke your proxy. |
TABLE OF CONTENTS
Proposal | Page Number | Vote Required for Approval | Voting Options | Effect of Votes Withheld/ Abstentions, As Applicable | Effect of Broker Non-Votes | ||||||||||||
Proposal No. 1: Reverse Stock Split(1) | 6 | FOR votes from the holders of a majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote | FOR, AGAINST or ABSTAIN | No effect | Not applicable | ||||||||||||
(1) | This proposal is considered to be a “routine” matter under NYSE rules. Accordingly, if you hold your shares in street name and do not provide voting instructions to your broker, bank or other agent that holds your shares, your broker, bank or other agent has discretionary authority to vote your shares on this proposal. |
TABLE OF CONTENTS
• | effect a reverse stock split (the “Reverse Stock Split”) of all of the outstanding shares of our common stock at a ratio of between 1-for-10 and 1-for-500, inclusive. |
TABLE OF CONTENTS
TABLE OF CONTENTS
Reverse Stock Split Ratio | — | 10:1 | 100:1 | 200:1 | 300:1 | 400:1 | 500:1 | ||||||||||||||
Number of shares of Common Stock Issued and Outstanding | 26,489,328 | 2,648,933 | 264,893 | 132,447 | 88,298 | 66,223 | 52,979 | ||||||||||||||
Number of Shares of Common Stock Reserved for Future Issuance(1) | 40,436,954 | 4,043,695 | 404,370 | 202,185 | 134,790 | 101,092 | 80,874 | ||||||||||||||
Number of Shares of Common Stock Authorized but Unissued and Unreserved | 143,073,718 | 14,307,372 | 1,430,737 | 715,369 | 476,912 | 357,684 | 286,147 | ||||||||||||||
(1) | Prior to giving effect to the Reverse Stock Split, consists of (i) 8,190,838 stock options outstanding; (ii) 2,963,612 pre-funded warrants outstanding; (iii) 21,054,613 warrants outstanding; (iv) 3,144,916 shares reserved for the conversion of $20.0 million of 13% senior secured notes (the “Convertible Securities Notes”) into shares of the Company’s common stock at a conversion price of $10.00 per share; (v) 2,127,237 shares reserved for future issuance under the Company’s 2024 Equity Incentive Plan; (vi) 2,514,445 shares reserved for future issuance under the Company’s 2024 Key Employee Equity Incentive Plan; and (vi) 441,293 shares reserved for future issuance under the Company’s 2024 Employee Stock Purchase Plan. |
• | each ten to five hundred shares of our common stock owned by a stockholder (depending on the Reverse Stock Split ratio selected by the Board), will be combined into one new share of our common stock; |
• | no fractional shares of common stock will be issued in connection with any Reverse Stock Split; instead, holders of common stock who would otherwise receive a fractional share of common stock pursuant to the Reverse Stock Split will receive cash in lieu of the fractional share as explained more fully below; |
• | based upon the Reverse Stock Split ratio selected by the Board, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, restricted stock units and warrants, which will result in a proportional decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock units and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants; and |
• | the number of shares then reserved for issuance under our equity compensation plans will be reduced proportionately based upon the Reverse Stock Split ratio selected by the Board (as described below). |
TABLE OF CONTENTS
TABLE OF CONTENTS
• | The reduced number of shares of our common stock resulting from a Reverse Stock Split could adversely affect the liquidity of our common stock. |
TABLE OF CONTENTS
• | The Reverse Stock Split could result in a significant devaluation of our market capitalization and the trading price of our common stock, on an actual or an as-adjusted basis, based on the experience of other companies that have effected reverse stock splits. |
• | The Reverse Stock Split may leave certain stockholders with one or more “odd lots,” which are stock holdings in amounts of less than 100 shares of our common stock. These odd lots may be more difficult to sell than shares of common stock in even multiples of 100. Additionally, any reduction in brokerage commissions resulting from the Reverse Stock Split may be offset, in whole or in part, by increased brokerage commissions required to be paid by stockholders selling odd lots created by the Reverse Stock Split. |
• | There can be no assurance that the market price per new share of our common stock after the Reverse Stock Split will increase in proportion to the reduction in the number of old shares of our common stock outstanding before the Reverse Stock Split. For example, based on the closing market price of our common stock on October 7, 2026 of $0.1284 per share of common stock, if the stockholders approve this proposal and the Board selects and implements a Reverse Stock Split ratio of 1-for-100, there can be no assurance that the post-split market price of our common stock would be $12.84 per share or greater. Accordingly, the total market capitalization of our common stock after the proposed Reverse Stock Split may be lower than the total market capitalization before the proposed Reverse Stock Split and, in the future, the market price of our common stock following the Reverse Stock Split may not exceed or remain higher than the market price prior to the proposed Reverse Stock Split. |
• | While the Board believes that a higher stock price may help generate investor interest, there can be no assurance that the Reverse Stock Split will result in a per share price that will attract institutional investors or investment funds or that such share price will satisfy the investing guidelines of institutional investors or investment funds. As a result, the trading liquidity of our common stock may not necessarily improve. |
• | If the Reverse Stock Split is effected and the market price of our common stock declines, the percentage decline may be greater than would occur in the absence of a Reverse Stock Split. The market price of our common stock will, however, also be based on our performance and other factors, which are unrelated to the number of shares outstanding. |
TABLE OF CONTENTS
• | an individual who is a citizen or resident of the United States or treated as a U.S. citizen or resident for U.S. federal income tax purposes; |
• | a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia; |
• | an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or |
• | a trust if (i) a U.S. court can exercise primary supervision over the trust’s administration and one or more “United States persons” (within the meaning of Section 7701(a)(30) of the Code) are authorized or have the authority to control all substantial decisions of the trust or (ii) it has a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | each director and nominee for director; |
• | each of the Company’s named executive officers; |
• | each person known by the Company to be the beneficial owner of more than 5% of the Company’s outstanding shares Common Stock; and |
• | all current executive officers and directors of the Company as a group |
Name and Address of Beneficial Owners(1) | Number of Shares | % | ||||
Current Executive Officers and Directors | ||||||
James L. Cox(2) | 480,698 | 1.78 | ||||
Deborah Kaster(3) | 436,009 | 1.62 | ||||
Sandra Gardiner(4) | 80,000 | * | ||||
Keyvan Mirsaeedi-Farahani(5) | 92,770 | * | ||||
Orly Mishan(6) | 266,666 | 1.00 | ||||
Timothy Moran(7) | 80,000 | * | ||||
Sean Salmon(8) | 37,500 | * | ||||
Todd Usen(9) | 1,079,670 | 3.95 | ||||
All current directors and executive officers as a group (eight individuals)(10) | 2,553,313 | 8.87 | ||||
Former Executive Officers | ||||||
Hakon Bergheim | 7,539 | * | ||||
Five Percent Holders | ||||||
Entities affiliated with Perceptive Advisors LLC(11) | 15,321,655 | 47.98 | ||||
Alyeska Master Fund, L.P.(12) | 2,583,733 | 9.26 | ||||
* | Less than 1% |
(1) | This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, the Company believes that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. The business address of each beneficial owner unless otherwise stated is 26051 Merit Cir #102, Laguna Hills, CA 92653. |
(2) | Consists of (a) 36,698 shares of common stock and (b) 444,000 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026. |
(3) | Consists of (a) 15,000 shares of common stock and (b) 421,009 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026. |
(4) | Consists of 80,000 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026. |
(5) | Consists of (i) 12,770 shares of common stock and (b) 80,000 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026. |
(6) | Consists of 266,666 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026. |
(7) | Consists of 80,000 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026. |
TABLE OF CONTENTS
(8) | Consists of 37,500 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026. |
(9) | Consists of (a) 207,315 shares of common stock and (b) 872,355 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026. |
(10) | Consists of (a) 271,783 shares of common stock and (b) 2,281,530 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026. |
(11) | Consists of (i) 9,675,684 shares of Common Stock directly held by Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”), (ii) warrants directly held by the Master Fund exercisable into 5,445,069 shares of Common Stock, and (iii) 200,902 shares of Common Stock directly held by C2 Life Sciences LLC (“C2”). Such amounts do not include shares of common stock issuable upon exercise of pre-funded warrants and warrants that may not be exercised if the aggregate number of shares of common stock beneficially owned by entities affiliated with Master Fund would exceed 9.99% of the total number of shares of our common stock then issued and outstanding after giving effect to such exercise. Perceptive Advisors LLC (the “Advisor”) serves as the investment manager of the Master Fund and C2. Joseph Edelman serves as the managing member of the Advisor. Accordingly, the Advisor and Mr. Edelman have voting and investment discretion with respect to, and may be deemed to beneficially own, the shares of Common Stock and warrants held of record by the Master Fund and C2. The Advisor does not directly hold any shares of Common Stock or warrants. The principal business address of each of these persons and entities is 51 Astor Place, 10th Floor, New York, NY 10003. |
(12) | Consists of (i) 1,159,615 shares of Common Stock and (ii) milestone warrants exercisable into shares of Common Stock, in each case held by Alyeska Master Fund, L.P. Alyeska Investment Group, L.P., the investment manager of Alyeska Master Fund, L.P., has voting and investment control of the shares held by Alyeska Master Fund, L.P. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to be the beneficial owner of such shares. Mr. Parekh, however, disclaims any beneficial ownership of the shares held by Alyeska Master Fund, L.P. The registered address of Alyeska Master Fund, L.P. is at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, KY1-1104, Cayman Islands. Alyeska Investment Group, L.P. is located at 77 W. Wacker, Suite 700, Chicago IL 60601. |
TABLE OF CONTENTS
TABLE OF CONTENTS
By Order of the Board of Directors | |||
/s/ Deborah Kaster | |||
Deborah Kaster | |||
Chief Financial Officer and Chief Business Officer | |||
October 13, 2026 | |||
TABLE OF CONTENTS
1. | The name of the corporation is Adagio Medical Holdings, Inc. (the “Corporation”). |
2. | The Corporation’s original Certificate of Incorporation was filed on July 29, 2024 (the “Certificate”) |
3. | The Corporation’s Board of Directors and stockholders, acting in accordance with the provisions of Sections 141 and 242 of the DGCL, adopted resolutions approving the following amendments to the Certificate: |
4. | All other provisions of the Certificate will remain in full force and effect. |
1 | These amendments approve the combination of any whole number of shares of the Company’s Common Stock between and including ten (10) and five hundred (500) into one (1) share of the Company’s Common Stock. By these amendments, the stockholders would approve each of the alternate amendments proposed by the Company’s Board of Directors. If the reverse stock split proposal is approved by stockholders, the Certificate of Amendment filed with the Secretary of State of the State of Delaware will include only that reverse stock split ratio determined by the Company’s Board of Directors to be in the best interests of the Company and its stockholders. The other amendments will be abandoned pursuant to Section 242(c) of the General Corporation Law of the State of Delaware. The Company’s Board of Directors may also elect not to effect any reverse stock split, in which case all proposed alternate amendments will be abandoned. |
TABLE OF CONTENTS
5. | This Certificate of Amendment has been duly adopted in accordance with the provisions of Section 242 of the DGCL. |
6. | This amendment to the Certificate of Incorporation shall be effective on and as of as of the effective time of 5:00 p.m., Eastern Time, on [•], 2026. |
TABLE OF CONTENTS
Adagio Medical Holdings, Inc. | ||||||
By: | ||||||
Name: | Todd Usen | |||||
Title: | Chief Executive Officer | |||||
TABLE OF CONTENTS

TABLE OF CONTENTS
